Pharmafile Logo

BIA elects six new board members

Biotech trade body adds representatives from MedImmune, J&J and more

BIA J and J Patrick VerheyenUK trade body the BioIndustry Association (BIA) has elected six new members to its board.

They comprise senior figures from different member companies of the organisation, which represents the biotech industry in the UK.

The list of new members includes Patrick Verheyen (pictured right), head of Johnson & Johnson’s innovation centre in London; Jane Osbourn of AstraZeneca subsidiary MedImmune; and Kevin Cox, CEO of imaging firm Imanova.

The remaining new appointments are Stephen Taylor of Fujifilm Diosynth Biotechnologies; Donna Hackett, director of life sciences consultancy firm KDH BioManagement; and Tim Watts, chief financial officer of Oxford BioMedica.

They will all serve from January 1, 2014, for term of three years.

The BIA also announced several returning board members, including John Brown of Vectura Group and Ian Tomlinson, senior VP of worldwide business development and biopharma research at GlaxoSmithKline.

“The appointees are recognised leaders of our industry and I look forward to working with them to help the BIA meet the needs of the bioscience sector in Europe’s strongest bioscience cluster,” said Edward Hodgkin, BIA chairman.

Article by Dominic Tyer
15th October 2013
From: Research
Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links